Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3867642 | 0.98 | MEN1 (0.37) | MEN1ALDH1A1MAPTPKMALOX15 | |
| Hydrochloric Acid SCHEMBL8129255 | 0.86 | MEN1 (0.32) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL20858625 | 0.78 | MAPK1 (0.31) | — | |
| SCHEMBL20816367 | 0.78 | MAPK1 (0.31) | — | |
| Hydrochloric Acid SCHEMBL21640781 | 0.77 | MAPK1 (0.31) | — | |
| SCHEMBL31030321 | 0.75 | — | — | |
| SCHEMBL4304621 | 0.73 | MEN1 (0.47) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL14704875 | 0.72 | MAPK1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL3869839 | 0.71 | ALDH1A1 (0.46) | MEN1ALDH1A1MAPTPKMALOX15 | |
| SCHEMBL31390572 | 0.71 | MAPK1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778957-B2 | CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| CN-100384856-C | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO INC (US) | 2008-04-30 | — | — | CN | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| CN-1805965-A | Modulators of chemokine receptor activity | MERCK & CO INC (US) | 2006-07-19 | — | — | CN | disclosed |
| CN-1787818-A | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO INC (US) | 2006-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | MEN1 3879/4885ALDH1A1 2646/4885MAPT 4627/4885 |
| US-20140275017-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | MEN1 717/4885ALDH1A1 1818/4885MAPT 3225/4885 |
| US-20120010193-A1 | CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | MEN1 756/4885ALDH1A1 1870/4885MAPT 3540/4885 |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | MEN1 1001/4885ALDH1A1 2836/4885MAPT 4195/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | MEN1 4791/4885ALDH1A1 534/4885MAPT 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.